An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically ...

UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...